Treece Medical (TMCI) Q1 2026: 35% Surgeon Adoption Drives Portfolio Expansion Despite 10% Revenue Decline
Treece Medical’s portfolio expansion strategy is gaining traction, as 35% of its surgeon base has adopted at least one of its three new bunion systems, offsetting headwinds from lower-priced product mix and macro-driven demand softness. The company’s disciplined approach to innovation and sales force leverage is broadening its total addressable market, with management reaffirming full-year guidance and signaling a return to growth in Q4. Investors should watch for accelerating procedure volumes and margin resilience as new launches ramp in the back half of 2026.
Summary
- Portfolio Adoption Momentum: New bunion systems now used by over a third of Treece’s surgeon base, accelerating procedure volume growth.
- Mix Shift Headwind: Lower ASP products and macro softness continue to pressure top-line, but margin discipline holds firm.
- Growth Inflection Ahead: Management expects revenue growth to return in Q4 as new launches and sales ramp offset earlier declines.
Business Overview
Treece Medical Concepts (TMCI) develops and commercializes surgical solutions for bunion and related foot and ankle procedures. The company generates revenue from the sale of proprietary implants, instruments, and biologics to orthopedic surgeons and hospitals, with its core business historically anchored in Lapoplasty, a 3D bunion correction system. TMCI’s portfolio now spans multiple bunion correction technologies (including nanoplasty and percuplasty MIS systems), great toe fusion (SPEED MTP), and a growing suite of adjacent fixation and biologic products, targeting expanded procedure types and surgeon preferences.
Performance Analysis
Treece Medical’s first quarter results reflect the dual impact of strategic portfolio expansion and persistent market headwinds. Revenue fell 10% year-over-year, driven by a shift toward lower-priced minimally invasive (MIS) products and continued softness in bunion procedure kit volumes. Gross margin held steady at 79.3%, underscoring management’s focus on maintaining profitability through disciplined product design and cost control, even as the product mix evolved. Operating expenses declined from the prior year, and cash usage improved, with the company exiting the quarter with $51.9 million in liquidity—an increase from year-end and a signal of improving operational discipline.
Procedure volume growth remained positive in the mid-single digits, a testament to the growing adoption of Treece’s new systems by both existing and new surgeons. Notably, 35% of the legacy Lapoplasty user base has now adopted at least one of the three new bunion systems, up from 25% in the prior quarter. Early evidence suggests that new product users are also beginning to adopt Lapoplasty, indicating cross-portfolio pull-through. While adjusted EBITDA loss widened, the company expects cash burn to halve in 2026 as operating leverage improves and higher-ASP product launches ramp in the second half.
- Surgeon Penetration Expands: 35% of Lapoplasty surgeons now use at least one new bunion system, driving incremental procedure growth.
- Mix Shift Weighs on ASP: Lower-priced MIS products adopted rapidly, creating a temporary revenue headwind until Q4 lapping.
- Margin Resilience: Gross margin remains in the high 70% range, despite mix pressure, as new products are engineered for profitability.
Management’s reaffirmed guidance for a return to revenue growth in Q4 hinges on continued adoption, new product launches, and a more favorable mix as higher-ASP midfoot and hindfoot solutions scale.
Executive Commentary
"As of Q1, approximately 35% of our lapoplasty surgeon user base has incorporated at least one of these three new bunion systems into their practice since launch. This represents an increase over the 25% that we reported in the fourth quarter of 2025."
John Treese, Chief Executive Officer
"We are very focused on gross margins here. Our new products, we really have a goal to launch new products that have consistent gross margins with what we've had historically...we believe that we can continue to do that going forward."
Mark Hare, Chief Financial Officer
Strategic Positioning
1. Portfolio Expansion and TAM Growth
Treece Medical is executing on a strategy to double its addressable market by broadening its bunion and adjacent procedure offerings. The three new bunion systems (nanoplasty, percuplasty, and SPEED MTP) now target the full spectrum of bunion correction and great toe arthrodesis, covering both osteotomy and fusion segments. The addition of SuperBite screws and SpeedXM fusion plates further extends reach into midfoot and hindfoot procedures, collectively expanding TAM by $300 million and increasing wallet share potential with existing surgeons.
2. Sales Force Leverage and Surgeon Utilization
The company’s strategy relies on leveraging its established sales force and surgeon relationships to drive cross-portfolio adoption. By equipping reps with a broader set of solutions, Treece reduces competitive rep presence in the OR and increases the likelihood of multiple product adoption per account. Early data shows new product adoption is not cannibalizing Lapoplasty, but instead is additive, capturing more of each surgeon’s caseload and fostering full-portfolio surgeons.
3. Innovation Pipeline and Margin Discipline
TMCI’s innovation cadence remains robust, with Lapoplasty Lightning, Speed TMT, and Intelliguide PSI set to launch in 2026, targeting improved procedural efficiency, reproducibility, and surgeon appeal. Importantly, management designs new products to deliver gross margins in line with legacy offerings, preserving profitability even as the portfolio mix shifts. This focus on margin discipline is critical as the company navigates temporary ASP headwinds from rapid MIS adoption.
4. Competitive Conversions and Market Share Gains
Treece is increasingly winning competitive accounts, as surgeons switch to its MIS systems and fusion offerings thanks to superior instrumentation and reproducible outcomes. The sales team’s expertise and the expanded product suite are enabling competitive displacement, particularly in the high-volume osteotomy and MTP fusion segments.
5. Cash Efficiency and Capital Allocation
Inventory discipline and capital-efficient product design underpin TMCI’s ability to scale without overextending resources. The SuperBite screw system, for example, was launched with a lean SKU count to minimize inventory burden. Cash usage is expected to fall by 50% in 2026, supporting ongoing investment in growth initiatives without balance sheet strain.
Key Considerations
Treece Medical’s Q1 results highlight the early success of its portfolio expansion strategy but also surface important considerations for forward investors. The strategic context is defined by balancing rapid adoption of lower-priced innovations with the need to sustain margin and reignite top-line growth as new launches scale.
Key Considerations:
- Surgeon Adoption Trajectory: The pace at which existing and new surgeons become “full-portfolio” users will determine the sustainability of procedure volume growth and wallet share gains.
- Mix Shift Lapping: Q4 marks the anniversary of major MIS launches; how quickly higher-ASP products offset mix pressure is central to the revenue reacceleration thesis.
- Pipeline Execution: Timely commercialization and uptake of Lapoplasty Lightning, SpeedXM, and SuperBite are critical for expanding into midfoot and hindfoot markets.
- Competitive Dynamics: Ongoing success in converting competitor accounts and defending share in core bunion procedures will shape long-term positioning.
- Margin and Cash Flow Discipline: Maintaining high gross margins and halving cash burn are essential for funding innovation and supporting valuation through the transition.
Risks
Key risks include continued macro-driven softness in elective procedure demand, which could delay the anticipated volume and revenue ramp, and the possibility that new product adoption cannibalizes rather than supplements Lapoplasty volumes. Execution risk remains high around the commercialization of new platforms and the ability to maintain gross margins as the product mix evolves. Competitive responses from larger orthopedic players, particularly in the MIS and fusion segments, could also pressure share gains or pricing.
Forward Outlook
For Q2 and Q3, Treece Medical expects:
- Continued revenue declines as mix shift dynamics persist until Q4 lapping.
- Stable gross margins in the high 70% range, supported by disciplined product design.
For full-year 2026, management reaffirmed guidance:
- Revenue of $202 million to $212 million, representing a decline of 5% to flat versus 2025.
- Adjusted EBITDA loss of $4 million to $6 million, with cash burn reduced by 50% year-over-year.
Management highlighted several factors that will drive the return to growth in Q4:
- Accelerating case volumes and expanded surgeon penetration.
- Favorable product mix as higher-ASP launches ramp and MIS headwinds lap.
Takeaways
Treece Medical’s Q1 2026 results reflect a company in strategic transition, leveraging innovation and sales force depth to expand its market while weathering near-term revenue headwinds. The return to growth narrative is contingent on the successful scaling of new products and continued margin discipline.
- Portfolio Expansion Delivers Early Wins: Rapid adoption of new bunion systems is driving mid-single-digit procedure growth, despite lower ASPs.
- Margin and Cash Control Provide Flexibility: High gross margins and reduced cash burn create room to invest in further innovation and sales initiatives.
- Growth Inflection Hinges on Q4 Execution: Investors should monitor the pace of adoption for higher-ASP launches and the lapping of mix headwinds as key catalysts for revenue reacceleration.
Conclusion
Treece Medical is executing a deliberate shift from a single-product company to a comprehensive bunion and foot solutions provider, with early adoption trends validating its approach. The next several quarters will be pivotal as higher-value products scale and the impact of mix headwinds recedes, setting up a potential return to growth and improved profitability in 2026 and beyond.
Industry Read-Through
Treece Medical’s experience underscores a broader medtech industry trend: portfolio breadth and procedural adjacencies are increasingly vital for driving surgeon loyalty and wallet share in a competitive, value-conscious environment. Rapid adoption of MIS and fusion technologies reflects shifting surgeon and patient preferences, with companies able to offer integrated, efficient solutions gaining share. The ability to launch new products without margin dilution and to leverage sales force relationships is becoming a key differentiator. Larger orthopedic players and pure-play disruptors alike will need to balance innovation cadence with profitability and capital efficiency as procedural demand remains sensitive to macro conditions and payer dynamics.